Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.35−0.06 (-4.26%)
Close on Nov 20, 2026Market cap $6.04MP/E –Yield –
Enveric Biosciences gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Enveric Biosciences's gross profit for the twelve months ending Sep 30, 2020 was $7.32M, down 12.1% year over year. For fiscal 2019 it was $8.15M, down 9.3% from the year before. The highest annual figure on record is $10.24M in fiscal 2017.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $8.15M | -9.3% |
| FY2018 | Dec 31, 2018 | $8.98M | -12.3% |
| FY2017 | Dec 31, 2017 | $10.24M | +47.8% |
| FY2016 | Dec 31, 2016 | $6.93M | +0.9% |
| FY2015 | Dec 31, 2015 | $6.87M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | $1.89M | -0.6% |
| Q2 FY2020 | Jun 30, 2020 | $1.82M | -23.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.88M | -12.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.73M | -9.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.90M | -19.0% |
| Q2 FY2019 | Jun 30, 2019 | $2.38M | -0.3% |
| Q1 FY2019 | Mar 31, 2019 | $2.14M | -8.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.91M | -6.6% |
| Q3 FY2018 | Sep 30, 2018 | $2.35M | -8.5% |
| Q2 FY2018 | Jun 30, 2018 | $2.39M | +2.4% |
| Q1 FY2018 | Mar 31, 2018 | $2.34M | -29.0% |
| Q4 FY2017 | Dec 31, 2017 | $2.04M | -1.3% |
| Q3 FY2017 | Sep 30, 2017 | $2.56M | +51.1% |
| Q2 FY2017 | Jun 30, 2017 | $2.33M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.07M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.70M | – |
See a number that looks wrong?